



In this report, “Arena Pharmaceuticals,” “Arena,” “Company,” “we,” “us” and “our” refer to Arena Pharmaceuticals, Inc., and one or more of our wholly owned subsidiaries, unless the context otherwise provides. Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2016, we issued a press release reporting our financial results for the first quarter ended March 31, 2016. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release issued May 9, 2016, reporting financial results for the first quarter ended March 31, 2016

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 9, 2016    Arena Pharmaceuticals, Inc.

By:            /s/ Steven W. Spector  
                 Steven W. Spector  
                 Executive Vice President, General Counsel and  
                 Secretary

EXHIBIT INDEX

Exhibit No. Description

99.1 Press release issued May 9, 2016, reporting financial results for the first quarter ended March 31, 2016